JOHNSON & JOHNSON (JNJ) Insider Transactions
Over the last 12 months, 22 JOHNSON & JOHNSON (JNJ) insiders filed 266 SEC Form 4 transactions: $257.7K in open-market purchases ( 1 distinct buyers) and $154.9M in open-market sales. 0% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $257.7KOpen-market buys (1y)
- $154.9MOpen-market sells (1y)
- 22Distinct insiders
- 266Transactions filed
- 0%Under Rule 10b5-1 plan
- 2026-09-08Latest filing
Recent Form 4 Filings Most recent 50 of 266 (1-year window)
Each row is a single Form 4 filing event for JNJ, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.
| Date | Insider | Title | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Pinto Daniel E | – | Grant | A | $31.3K | 113 | $276.3 |
| 2026-09-08 | Woods Eugene A. | – | Grant | A | $37.5K | 136 | $276.3 |
| 2026-09-08 | HEWSON MARILLYN A | – | Grant | A | $50.0K | 181 | $276.3 |
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | Exercise | M | $1.5M | 11,070 | $131.9 |
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | Exercise | M | $3.4M | 22,527 | $151.4 |
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | Exercise | M | $0 | 11,070 | $0.0 |
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | Exercise | M | $0 | 22,527 | $0.0 |
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | S | $3.0M | 11,070 | $274.7 |
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | S | $6.2M | 22,527 | $274.7 |
| 2026-08-17 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Exercise | M | $1.7M | 15,000 | $115.7 |
| 2026-08-17 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Exercise | M | $0 | 15,000 | $0.0 |
| 2026-08-17 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | S | $4.0M | 15,000 | $263.4 |
| 2026-08-13 | Duato Joaquin | CEO and Chairman of the Board | Exercise | M | $14.3M | 123,291 | $115.7 |
| 2026-08-13 | Duato Joaquin | CEO and Chairman of the Board | Exercise | M | $0 | 123,291 | $0.0 |
| 2026-08-13 | Duato Joaquin | CEO and Chairman of the Board | Sell | S | $5.5M | 20,976 | $262.0 |
| 2026-08-13 | Duato Joaquin | CEO and Chairman of the Board | Sell | S | $26.7M | 102,315 | $261.0 |
| 2026-08-06 | Forminard Elizabeth | EVP, Chief Legal Officer | Exercise | M | $1.2M | 9,344 | $131.9 |
| 2026-08-06 | Forminard Elizabeth | EVP, Chief Legal Officer | Exercise | M | $0 | 9,344 | $0.0 |
| 2026-08-06 | Forminard Elizabeth | EVP, Chief Legal Officer | Sell | S | $2.4M | 9,344 | $257.8 |
| 2026-08-06 | Forminard Elizabeth | EVP, Chief Legal Officer | Sell | S | $1.7M | 6,574 | $255.9 |
| 2026-08-05 | Duato Joaquin | CEO and Chairman of the Board | Sell | S | $10.8M | 41,957 | $258.1 |
| 2026-08-05 | Duato Joaquin | CEO and Chairman of the Board | Sell | S | $1.7M | 6,523 | $258.7 |
| 2026-07-20 | Broadhurst Vanessa | EVP, Global Corp Affairs | Exercise | M | $1.4M | 11,129 | $129.5 |
| 2026-07-20 | Broadhurst Vanessa | EVP, Global Corp Affairs | Exercise | M | $1.6M | 11,925 | $131.9 |
| 2026-07-20 | Broadhurst Vanessa | EVP, Global Corp Affairs | Exercise | M | $0 | 11,129 | $0.0 |
| 2026-07-20 | Broadhurst Vanessa | EVP, Global Corp Affairs | Exercise | M | $0 | 11,925 | $0.0 |
| 2026-07-20 | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell | S | $5.8M | 23,054 | $251.3 |
| 2026-06-11 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Exercise | M | $1.2M | 10,000 | $115.7 |
| 2026-06-11 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Exercise | M | $0 | 10,000 | $0.0 |
| 2026-06-11 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | S | $2.4M | 10,000 | $241.2 |
| 2026-06-09 | Woods Eugene A. | – | Grant | A | $37.5K | 161 | $232.8 |
| 2026-06-09 | Pinto Daniel E | – | Grant | A | $31.2K | 134 | $232.8 |
| 2026-06-09 | HEWSON MARILLYN A | – | Grant | A | $50.0K | 215 | $232.8 |
| 2026-05-01 | REED JOHN C | EVP, Innovative Medicine, R&D | Exercise | M | $0 | 25,255 | $0.0 |
| 2026-05-01 | REED JOHN C | EVP, Innovative Medicine, R&D | Exercise | M | $0 | 25,255 | $0.0 |
| 2026-05-01 | REED JOHN C | EVP, Innovative Medicine, R&D | Other | F | $2.5M | 11,002 | $229.8 |
| 2026-04-23 | Woods Eugene A. | – | Grant | A | $0 | 975 | $0.0 |
| 2026-04-23 | West Nadja | – | Grant | A | $0 | 975 | $0.0 |
| 2026-04-23 | WEINBERGER MARK A | – | Grant | A | $0 | 975 | $0.0 |
| 2026-04-23 | Pinto Daniel E | – | Grant | A | $0 | 1,712 | $0.0 |
| 2026-04-23 | MORIKIS JOHN G | – | Grant | A | $0 | 1,540 | $0.0 |
| 2026-04-23 | McClellan Mark B. | – | Grant | A | $0 | 975 | $0.0 |
| 2026-04-23 | Joly Hubert | – | Grant | A | $0 | 975 | $0.0 |
| 2026-04-23 | Johnson Paula A | – | Grant | A | $0 | 975 | $0.0 |
| 2026-04-23 | HEWSON MARILLYN A | – | Grant | A | $0 | 975 | $0.0 |
| 2026-04-23 | Doudna Jennifer A | – | Grant | A | $0 | 975 | $0.0 |
| 2026-04-23 | Beckerle Mary C | – | Grant | A | $0 | 975 | $0.0 |
| 2026-03-10 | HEWSON MARILLYN A | – | Grant | – | $50.0K | 206 | $242.1 |
| 2026-03-10 | Pinto Daniel E | – | Grant | – | $31.3K | 129 | $242.1 |
| 2026-03-10 | Woods Eugene A. | – | Grant | – | $37.5K | 155 | $242.1 |
Showing the most recent 50 of 266 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.
Top Insider Buyers of JNJ By dollar volume, 1-year window
- MORIKIS JOHN G $257.7K
Methodology & FAQ
How We Track JNJ Insider Transactions
Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.
What is an SEC Form 4 filing for JOHNSON & JOHNSON?
Form 4 is a transaction-level disclosure that corporate insiders (officers, directors, and beneficial owners of more than 10% of a registered class of equity securities) must file with the SEC within two business days of any change in their beneficial ownership of JOHNSON & JOHNSON (JNJ) shares.
What is a Rule 10b5-1 trading plan?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.
How is "insider buying" different from a stock grant or option exercise?
An insider buy (SEC transaction code P) is an open-market purchase of JOHNSON & JOHNSON (JNJ) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.
How recent is the data?
Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.